Senna 7.5mg tablets 12 Years Plus

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Senna fruit

Available from:

Aspar Pharmaceuticals Ltd

ATC code:

A06AB06

INN (International Name):

Senna fruit

Dosage:

7.5mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 01060200; GTIN: 5024071250022

Patient Information leaflet

Black
Profile
FACE
FACE
FACE
FACE
FACE
FACE
FACE
FACE
Aspar Pharmaceuticals Ltd
STL02-1
12109928
1
120 x 220mm
Aspar Senna 7.5mg (12 Years+) PIL V7 AW(O).pdf
David Hicks
Michelle Beckwith
07/09/2021
1
Aspar Senna Tabs 7.5mg 12 Years Plus Leaflet - Front
Black
Profile
REV
REV
REV
REV
REV
REV
REV
REV
Aspar Pharmaceuticals Ltd
STL02-1
12109928
1
120 x 220mm
Aspar Senna 7.5mg (12 Years+) PIL V7 AW(O).pdf
David Hicks
Michelle Beckwith
07/09/2021
1
Aspar Senna Tabs 7.5mg 12 Years Plus Leaflet - Reverse

Summary of Product characteristics

1
NAME OF THE MEDICINAL PRODUCT
Senna 7.5 mg Tablets 12 Years Plus
Numark Senna 7.5 mg Tablets 12 Years Plus
Careway Senna 7.5 mg Tablets 12 Years Plus
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains powdered Senna Pods (fruit)
_(_
_Senna alexandrina _Mill. (syn. _Cassia _
_acutifolia _Delile and _Cassia angustifolia _Vahl)) equivalent to 7.5
mg of hydroxyanthracene
glycosides, calculated as sennoside B
Excipient with known effect:
Each tablet contains 153 mg of lactose monohydrate / anhydrous (See
section 4.4 Special
Warnings and Precautions for Use)
For full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Tablets
Round biconvex uncoated greenish-brown tablets with a diameter of
approximately 9 mm
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the short-term relief of occasional constipation.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Method of administration:
For oral administration only.
Posology:
The correct individual dose is the smallest required to produce a
comfortable soft-formed motion.
ADULTS. THE ELDERLY AND CHILDREN OVER 12 YEARS OF AGE: Take one to two
tablets at night when
required. A higher dose may be prescribed under medical guidance. The
maximum daily dose of
hydroxyanthracene glycosides is 30mg.
Should not be used in children or adolescents under the age of 12
years (see section 4.3).
New users should start with the lowest dose and increase it to the
maximum dose if necessary. Once
regularity has been regained dosage should be reduced and can usually
be stopped.
If no bowel movement has occurred after 3 days a doctor or a qualified
healthcare practitioner should
be consulted.
Duration of use:
Not to be used for more than 1 week. Usually it is sufficient to take
this medicinal product up to two
to three times a week.
Use for more than 1-2 weeks requires medical supervision.
If the symptoms persist or worsen during the use of a medicinal
product, a doctor should be consulted.
See also section 4.4 Special warnings and precautions for use.
4.3
CONTRAINDICATIONS
Hyp